Loading...
•
Sep 30, 2024
Soleno Therapeutics Q3 2024 Earnings Report
Soleno Therapeutics reported financial results for Q3 2024 and provided a corporate update.
Key Takeaways
Soleno Therapeutics reported a net loss of $76.6 million for the third quarter ended September 30, 2024. The FDA accepted the NDA for DCCR with a PDUFA target action date of December 27, 2024.
The FDA accepted the NDA for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) and granted Priority Review.
The FDA's target action date is December 27, 2024.
Soleno appointed Dawn Carter Bir to its Board of Directors and Matthew Pauls assumed the role of Lead Independent Director.
Soleno mourned the passing of former Chairman of the Board Ernest Mario.
Forward Guidance
This press release contains forward-looking statements regarding the timing of any regulatory process or ultimate approvals and determining a path forward for DCCR for the treatment of PWS.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...